BRPI0915137A2 - uso de pelo menos um composto, peptídeo, e, formulação farmacêutica - Google Patents

uso de pelo menos um composto, peptídeo, e, formulação farmacêutica

Info

Publication number: BRPI0915137A2
Authority: BR; Brazil
Prior art keywords: peptide; compound; pharmaceutical formulation; formulation; pharmaceutical
Prior art date: 2008-06-12

Application number

BRPI0915137A

Other languages

English (en)

Inventor

Andrea Dolischka

Christian Gieffers

Frank Mattner

Markus Mandler

Oleksandr Otava

Original Assignee

Affiris Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-12

Filing date

2009-06-12

Publication date

2016-02-16

2009-06-12 Application filed by Affiris Ag filed Critical Affiris Ag

2016-02-16 Publication of BRPI0915137A2 publication Critical patent/BRPI0915137A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0915137A 2008-06-12 2009-06-12 uso de pelo menos um composto, peptídeo, e, formulação farmacêutica BRPI0915137A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0095108A AT506819B1 (de)	2008-06-12	2008-06-12	Vakzin zur behandlung von alzheimer-krankheit
PCT/AT2009/000236 WO2009149486A2 (en)	2008-06-12	2009-06-12	Compounds for treating diseases

Publications (1)

Publication Number	Publication Date
BRPI0915137A2 true BRPI0915137A2 (pt)	2016-02-16

Family

ID=41401982

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0915137A BRPI0915137A2 (pt)	2008-06-12	2009-06-12	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica

Country Status (21)

Country	Link
US (2)	US8613931B2 (pt)
EP (1)	EP2310034B9 (pt)
JP (2)	JP2011522841A (pt)
KR (1)	KR20110036808A (pt)
CN (1)	CN102123727B (pt)
AT (3)	AT506819B1 (pt)
AU (1)	AU2009257169B2 (pt)
BR (1)	BRPI0915137A2 (pt)
CA (1)	CA2723991A1 (pt)
CY (1)	CY1115316T1 (pt)
DK (1)	DK2310034T3 (pt)
ES (1)	ES2461492T3 (pt)
HR (1)	HRP20140586T1 (pt)
IL (1)	IL209895A (pt)
MX (1)	MX2010013648A (pt)
PL (1)	PL2310034T3 (pt)
PT (1)	PT2310034E (pt)
RS (1)	RS53236B (pt)
RU (1)	RU2553345C2 (pt)
SI (1)	SI2310034T1 (pt)
WO (1)	WO2009149486A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2576617B1 (en)	2010-06-04	2016-04-27	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin	MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
US20120328605A1 (en) *	2010-10-27	2012-12-27	Daniel Larocque	Compositions and uses
US9617302B2 (en) *	2011-06-14	2017-04-11	National Taiwan University	Peptide compounds for inhibition of platelet aggregation
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
DK2579042T3 (da)	2011-10-04	2014-07-21	Affiris Ag	Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
EP2659908A1 (en)	2012-05-01	2013-11-06	Affiris AG	Compositions
EP2787347A1 (en)	2013-04-03	2014-10-08	Affiris AG	Method for detecting Aß-specific antibodies in a biological sample
WO2015165964A1 (en) *	2014-04-29	2015-11-05	Affiris Ag	Treatment and prevention of alzheimer's disease (ad)
FI3137094T3 (fi)	2014-04-29	2023-03-20	Advantage Therapeutics Inc	Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
WO2015165961A1 (en)	2014-04-29	2015-11-05	Affiris Ag	Treatment and prevention of alzheimer's disease (ad)
WO2015175769A1 (en)	2014-05-15	2015-11-19	Biogen Ma Inc.	Methods for the detection of amyloid beta oligomers in biological samples
KR20180094876A (ko)	2015-11-09	2018-08-24	더 유니버시티 오브 브리티쉬 콜롬비아	아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004494A1 (en) *	2015-11-09	2017-05-18	The University Of British Columiba	Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10772969B2 (en) *	2015-11-09	2020-09-15	The University Of British Columbia	N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
ES2571055B1 (es) *	2016-02-15	2016-12-28	Araclon Biotech, S.L.	Conjugado amiloide y usos y procedimientos del mismo
KR20230109776A (ko) *	2016-06-29	2023-07-20	더 리전츠 오브 더 유니버시티 오브 캘리포니아	알파-시누클레인 응집의 구조-기반 펩타이드 저해제
AU2017299858B2 (en)	2016-07-18	2024-07-25	Promis Neurosciences, Inc.	Antibodies to Amyloid beta
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
JP7761373B2 (ja) *	2017-05-30	2025-10-28	ザユニヴァーシティオブブリティッシュコロンビア	Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
CN109985231A (zh) *	2018-01-02	2019-07-09	上海清流生物医药科技有限公司	一种蛋白在制备预防和治疗痴呆症的药物中的应用
PH12022553234A1 (en)	2020-05-19	2024-02-12	Othair Prothena Ltd	Multi-epitope vaccine for the treatment of alzheimer`s disease
AU2021345451A1 (en) *	2020-09-17	2023-04-13	Othair Prothena Limited	Beta-amyloid vaccine for the treatment of alzheimer's disease
CN112608926A (zh) *	2020-12-08	2021-04-06	安徽大千生物工程有限公司	一种用于检测β淀粉样蛋白的基因序列组、杂交瘤细胞组及胶乳增强免疫比浊法试剂盒
CN113061161B (zh) *	2021-04-02	2023-09-12	河南省农业科学院动物免疫学重点实验室	靶向amyloid-beta结构的抑制性肽配基及应用
TW202334200A (zh) *	2021-10-28	2023-09-01	美商艾伯維有限公司	抗澱粉樣蛋白β抗體及其使用方法
AU2023223603A1 (en)	2022-02-28	2024-08-22	Tridem Bioscience Gmbh & Co Kg	A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20110131679A2 (en) *	2000-04-19	2011-06-02	Thomas La Rosa	Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
RU2294211C2 (ru) *	2001-01-19	2007-02-27	Цитос Байотекнолоджи Аг	Композиция и способ для иммунизации, способ продуцирования неприродного, упорядоченного и повторяющегося массива антигенов
US20040265849A1 (en)	2002-11-22	2004-12-30	Applera Corporation	Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
AT413945B (de)	2003-01-14	2006-07-15	Mattner Frank Dr	Impfstoff für die alzheimer-krankheit
US7358331B2 (en) *	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
WO2005023985A2 (en) *	2003-09-03	2005-03-17	University Of Rochester	Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
US20050176030A1 (en)	2003-10-28	2005-08-11	Li Gan	Regulated nucleic acids in pathogenesis of Alzheimer's Disease
AT500483B1 (de) *	2004-07-13	2006-01-15	Mattner Frank Dr	Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de)	2004-07-13	2006-07-15	Mattner Frank Dr	Impfstoff gegen die alzheimer-krankheit
GB0421639D0 (en)	2004-09-29	2004-10-27	Proteome Sciences Plc	Methods and compositions relating to alzheimer's disease
US7780963B2 (en)	2004-10-25	2010-08-24	Merck & Co., Inc.	Anti-ADDL antibodies and uses thereof
EP2441470B1 (en) *	2006-03-14	2014-05-07	Oregon Health and Science University	Methods for producing an immune response to tuberculosis
WO2008002893A2 (en)	2006-06-29	2008-01-03	Centocor, Inc.	Anti-amyloid antibodies, compositions, methods and uses
US20120017338A1 (en) *	2008-01-15	2012-01-19	Wei Wu	Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits

2008
- 2008-06-12 AT AT0095108A patent/AT506819B1/de not_active IP Right Cessation
2009
- 2009-06-12 AU AU2009257169A patent/AU2009257169B2/en not_active Ceased
- 2009-06-12 BR BRPI0915137A patent/BRPI0915137A2/pt not_active IP Right Cessation
- 2009-06-12 CN CN200980131375.9A patent/CN102123727B/zh not_active Expired - Fee Related
- 2009-06-12 JP JP2011512781A patent/JP2011522841A/ja active Pending
- 2009-06-12 EP EP09761153.7A patent/EP2310034B9/en active Active
- 2009-06-12 HR HRP20140586AT patent/HRP20140586T1/hr unknown
- 2009-06-12 WO PCT/AT2009/000236 patent/WO2009149486A2/en not_active Ceased
- 2009-06-12 PL PL09761153T patent/PL2310034T3/pl unknown
- 2009-06-12 RU RU2011100126/15A patent/RU2553345C2/ru not_active IP Right Cessation
- 2009-06-12 MX MX2010013648A patent/MX2010013648A/es active IP Right Grant
- 2009-06-12 DK DK09761153.7T patent/DK2310034T3/da active
- 2009-06-12 RS RS20140145A patent/RS53236B/sr unknown
- 2009-06-12 KR KR1020117000814A patent/KR20110036808A/ko not_active Ceased
- 2009-06-12 SI SI200930901T patent/SI2310034T1/sl unknown
- 2009-06-12 CA CA2723991A patent/CA2723991A1/en not_active Abandoned
- 2009-06-12 ES ES09761153.7T patent/ES2461492T3/es active Active
- 2009-06-12 US US12/997,674 patent/US8613931B2/en not_active Expired - Fee Related
- 2009-06-12 PT PT97611537T patent/PT2310034E/pt unknown
- 2009-12-11 AT AT0196409A patent/AT509106B1/de not_active IP Right Cessation
- 2009-12-11 AT AT0196309A patent/AT509105B1/de not_active IP Right Cessation
2010
- 2010-12-09 IL IL209895A patent/IL209895A/en not_active IP Right Cessation
2013
- 2013-03-15 US US13/838,152 patent/US20130230545A1/en not_active Abandoned
2014
- 2014-06-23 CY CY20141100458T patent/CY1115316T1/el unknown
2015
- 2015-03-04 JP JP2015042921A patent/JP6041917B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2009149486A3 (en)	2010-06-10
EP2310034B9 (en)	2014-12-17
AT509105B1 (de)	2011-12-15
AU2009257169A1 (en)	2009-12-17
CA2723991A1 (en)	2009-12-17
IL209895A (en)	2015-09-24
AT509106B1 (de)	2011-12-15
EP2310034A2 (en)	2011-04-20
IL209895A0 (en)	2011-02-28
US20110097351A1 (en)	2011-04-28
AU2009257169B2 (en)	2015-06-25
JP2015147771A (ja)	2015-08-20
RU2011100126A (ru)	2012-07-20
CN102123727A (zh)	2011-07-13
JP2011522841A (ja)	2011-08-04
KR20110036808A (ko)	2011-04-11
AT509105A1 (de)	2011-06-15
MX2010013648A (es)	2011-04-05
ES2461492T3 (es)	2014-05-20
WO2009149486A2 (en)	2009-12-17
SI2310034T1 (sl)	2014-05-30
US8613931B2 (en)	2013-12-24
DK2310034T3 (da)	2014-04-28
AT506819A1 (de)	2009-12-15
EP2310034B1 (en)	2014-03-26
AT506819B1 (de)	2011-06-15
RU2553345C2 (ru)	2015-06-10
HRP20140586T1 (hr)	2014-09-12
RS53236B (sr)	2014-08-29
CN102123727B (zh)	2015-06-10
HK1152470A1 (en)	2012-03-02
PL2310034T3 (pl)	2014-08-29
AT509106A1 (de)	2011-06-15
US20130230545A1 (en)	2013-09-05
CY1115316T1 (el)	2017-01-04
JP6041917B2 (ja)	2016-12-14
PT2310034E (pt)	2014-06-05

Publication	Publication Date	Title
BRPI0915137A2 (pt)	2016-02-16	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0915136A2 (pt)	2019-09-24	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0908097A2 (pt)	2015-12-01	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0810161A2 (pt)	2014-12-30	Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0921699A2 (pt)	2016-02-16	complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI0915120A2 (pt)	2016-07-26	composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto

Legal Events

Date	Code	Title	Description
2017-04-11	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-08-01	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]